Studying microbes and genes in prostate cancer and disease stage
Examines germs, antibiotic resistance and gene variants in adults with prostate cancer before biopsy.
Plain-language title generated from the registry record
Registry title: Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage
Key facts
- Where
- Kaunas, LithuaniaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06505356, who can take part
Where in Lithuania
- Lithuanian University of Health SciencesKaunas, LithuaniaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Edgaras Burzinskis
- Trial code
- NCT06505356
- Record updated
- 13 March 2025
- Original description
1. Identify the local inflammatory response in prostate tissue and the systemic response in the blood of patients with prostate cancer, depending on the stage of the disease, and evaluate their prognostic value. 2. Identify the spectrum of microorganisms and antibiotic resistance in patients with prostate cancer prior to prostate biopsy, and assess the risk of complications when using Ciprofloxacin and Fosfomycin. 3. Determine the significance of GAS5, JAZF1, and CTBP2 gene polymorphisms in the development of prostate cancer. 4. Evaluate the association of a specific gene polymorphism with the clinical course of the disease in patients with prostate cancer.Read full original descriptionShow less
Characterization of Microbiological and Genetic Features in Prostate Cancer Patients and Their Associations with Disease Stage and Clinical Presentation
1. Identify the local inflammatory response in prostate tissue and the systemic response in the blood of patients with prostate cancer, depending on the stage of the disease, and evaluate their prognostic value. 2. Identify the spectrum of microorganisms and antibiotic resistance in patients with prostate cancer prior to prostate biopsy, and assess the risk of complications when using Ciprofloxacin and Fosfomycin. 3. Determine the significance of GAS5, JAZF1, and CTBP2 gene polymorphisms in the development of prostate cancer. 4. Evaluate the association of a specific gene polymorphism with the clinical course of the disease in patients with prostate cancer.
Inclusion: Age: Male patients aged 18 years and older; Diagnosis: Patients who are suspected of having prostate cancer based on clinical data and standard diagnostic protocols; Disease Stage: Patients at any stage of suspected prostate cancer (localized, locally advanced, or metastatic); Consent: Ability and willingness to provide written informed consent; Clinical Data Availability: Availability of comprehensive clinical data; Sample Provision: Willingness to provide blood and/or tissue samples for genetic and inflammatory marker analysis.
Exclusion: Prior Treatment: Patients who have undergone any prior prostate cancer treatments such as surgery, radiation therapy, or systemic therapies (e.g., hormone therapy, chemotherapy); Other Malignancies: Presence of other concurrent malignancies, except for adequately treated basal cell or squamous cell skin cancer; Medication Use: Use of medications that could interfere with the study results, such as immunosuppressive drugs; Additional Considerations:; Severe Comorbidities: Patients with severe or uncontrolled comorbid conditions that could interfere with study participation or data interpretation (e.g., severe cardiovascular, pulmonary, hepatic, or renal diseases); Infection: Active infections or other severe medical conditions that could compromise patient safety or study integrity; Non-compliance: Inability to comply with study procedures, follow-up requirements, or any condition that, in the investigator's opinion, could interfere with study participation; Follow-Up: Participants should be willing to attend regular follow-up visits for ongoing data collection and monitoring of disease progression and treatment response; By setting these criteria, the study aims to create a well-defined patient cohort for evaluating the relationship between genetic and inflammatory markers and prostate cancer aggressiveness; Screening: All potential participants will undergo a screening process to verify eligibility criteria; Confidentiality: Ensure all patient data is handled in accordance with privacy regulations and ethical guidelines.